First universal newborn screening program for severe combined immunodeficiency in Europe. Three-years' experience in Catalonia.

• Published in: Revista espanola de salud publica Vol. 94
• Main Authors: Argudo Ramírez, Ana, Martín Nalda, Andrea, Marín Soria, José Luis, López Galera, Rosa María, González de Aledo Castillo, José Manuel, Pajares García, Sonia, Rivière, Jacques G, Martínez Gallo, Mónica, Colobran, Roger, Parra Martínez, Alba, Ribes Rubio, Antonia, Fernández Bardon, Rosa María, Asso Ministral, Laia, Prats Viedma, Blanca, García Villoria, Judit, Soler Palacín, Pere
• Format: Journal Article
• Language: Spanish
• Published: Spain 16-12-2020
• Subjects: Biomarkers - blood; Europe; Female; Humans; Incidence; Infant, Newborn; Male; Neonatal Screening - methods; Receptors, Antigen, T-Cell - blood; Severe Combined Immunodeficiency - blood; Severe Combined Immunodeficiency - diagnosis; Severe Combined Immunodeficiency - epidemiology; Spain - epidemiology; Europe; Spain; Severe combined immunodeficiency; PNP deficiency; Newborn screening; TREC; Catalonia Newborn Screening Program; SCID; Spain
• ISSN: 2173-9110

Severe combined immunodeficiency (SCID), the most severe form of T-cell immunodeficiency, can be screened at birth by quantifying T-cell receptor excision circles (TREC) in dried blood spot (DBS) samples. Early detection of this condition speeds up the establishment of appropriate treatment and increases the patient's life expectancy. Newborn screening for SCID started in January 2017 in Catalonia, the first Spanish and European region to universally include this testing. The results obtained in the first three years and a half of experience (January 2017 - June 2020) are shown here, using EnLite Neonatal TREC kit (Perkin Elmer) with 20 copies/µL as TREC detection cutoff. Of 222,857 newborns screened, 48 tested positive: three patients were diagnosed with SCID (incidence 1:74,285); 17 patients had clinically significant T-cell lymphopenia (non-SCID) with an incidence of 1 in 13,109 newborns; twenty two patients were considered false-positive cases because of an initially normal lymphocyte count with normalization of TREC between 3 and 6 months of life; one case had transient lymphopenia due to an initially low lymphocyte count with recovery in the following months; and five patients are still under study. The results obtained provide further evidence of the benefits of including this disease in newborn screening programs. Even longer follow-up could be necessary to define the exact incidence of SCID in Catalonia.